LLY catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
- Completion LockedPhase 2NCT01594723A Study of LY2784544 in Participants With Myeloproliferative NeoplasmsEli Lilly and Company · Neoplasms, HematologicActive, not recruitingLLYLead
- Enrollment
- Locked
- Primary completion
- Mar 20, 2015Actual
- Interventions
- Locked
- Completion LockedPhase 1NCT02057133A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has SpreadEli Lilly and Company · Breast NeoplasmsActive, not recruitingLLYLead
- Enrollment
- Locked
- Primary completion
- Mar 15, 2021Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT02152631A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung CancerEli Lilly and Company · Non Small Cell Lung CancerActive, not recruitingLLYLead
- Enrollment
- Locked
- Primary completion
- Sep 15, 2017Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT02246621A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast CancerEli Lilly and Company · Breast CancerActive, not recruitingLLYLead
- Enrollment
- Locked
- Primary completion
- Jan 31, 2017Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT02411448A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive...Eli Lilly and Company · Metastatic Non-Small Cell Lung CancerActive, not recruitingLLYLead
- Enrollment
- Locked
- Primary completion
- Jan 23, 2019Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT02711553A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract CancerEli Lilly and Company · Biliary Tract CancerActive, not recruitingLLYLead
- Enrollment
- Locked
- Primary completion
- Feb 16, 2018Actual
- Interventions
- Locked
- Completion LockedPhase 1NCT02779751A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast CancerEli Lilly and Company · Non Small Cell Lung CancerActive, not recruitingLLYLeadMRKCollaborator
- Enrollment
- Locked
- Primary completion
- Feb 3, 2020Actual
- Interventions
- Locked
- Completion LockedPhase 2/Phase 3NCT03706365A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate CancerEli Lilly and Company · Prostate CancerActive, not recruitingLLYLead
- Enrollment
- Locked
- Primary completion
- Jan 2, 2024Actual
- Interventions
- Locked
- Completion LockedPhase 1NCT05307705A Study of LOXO-783 in Patients With Breast Cancer/Other Solid TumorsEli Lilly and Company · Breast CancerActive, not recruitingLLYLead
- Enrollment
- Locked
- Primary completion
- Apr 2, 2025Actual
- Interventions
- Locked
- Completion LockedPhase 1NCT05509790A Study of LY3484356 in Chinese Participants With Advanced Breast CancerEli Lilly and Company · Breast NeoplasmsActive, not recruitingLLYLead
- Enrollment
- Locked
- Primary completion
- Feb 18, 2024Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT05559359A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic DermatitisEli Lilly and Company · Atopic DermatitisActive, not recruitingLLYLead
- Enrollment
- Locked
- Primary completion
- Jan 14, 2026Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT06662383A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have ObesityEli Lilly and Company · ObesityActive, not recruitingLLYLead
- Enrollment
- Locked
- Primary completion
- Nov 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT06914895A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or OverweightEli Lilly and Company · Type 1 DiabetesActive, not recruitingLLYLead
- Enrollment
- Locked
- Primary completion
- Nov 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT07215312A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal InsulinEli Lilly and Company · Diabetes Mellitus, Type 2Active, not recruitingLLYLead
- Enrollment
- Locked
- Primary completion
- Nov 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07225556A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise HealthyEli Lilly and Company · OverweightActive, not recruitingLLYLead
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07738614A Study of Eloralintide (LY3841136) in Participants With Obesity or OverweightEli Lilly and Company · ObesityActive, not recruitingLLYLead
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT06982859A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes...Eli Lilly and Company · Diabetes MellitusActive, not recruitingLLYLead
- Enrollment
- Locked
- Primary completion
- Jan 2027Sponsor estimate
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 17 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.